US FDA Hoping To Spur More ANDA Pre-Submission Meetings During GDUFA III

 
• By Derrick Gingery
Increase certainty
The FDA believes increasing pre-submission meetings for complex generic applications could boost first-cycle approvals. • Source: Alamy

More from Generics

More from Biosimilars & Generics